Personalized
GLP-1 Dosing for Better Clinical Outcomes

  • Personalized dosing suggestions

  • Visualize patient weight loss journeys

  • Improve shared decision-making

  • Shareable patient report with treatment progress

15K+

patients

Built from insights across clinical studies and real‑world practice

29

studies

Informed by clinical trials
and PK/PD models

60% of Patients Discontinue GLP-1 Treatment at 12 Months[1]

WeDosify helps clinicians deliver the right dose, at the right time, improving adherence and protecting revenue.

Personalize Treatment

Optimize treatment with dosing tailored to individual characteristics and response.
A simple line graph with an upward trending line in purple on a white circular background.

Increase Adherence

Reduce dropouts by empowering patients with insights into their weight loss journey.
A purple outline of a star inside a white circle with a black border.

Improve Patient Satisfaction

Response prediction helps patients achieve weight loss goals while minimizing the risk of side effects.
A simple rocket icon in dark purple on a white circular background.

Differentiate Your Service

Stand out with data-driven, personalized care that supports patients achieving their goals.

95% of GLP-1 patients surveyed (n=21) want a report from their provider that shares treatment option information.

Key Features

A screenshot showing a treatment options table and a graph illustrating predicted weight loss over time. The table lists three options with different remaining times to the goal (26, 32, 34 weeks) and maximum doses (1.0 mg, 1.0 mg, 2.4 mg). The graph plots weight loss percentages over weeks, with three lines representing different treatment regimens, showing decreasing weight loss over time.
Icon of two user profiles with a plus sign and checkmark, indicating adding or confirming a user.

Generate personalized dose regimens, whether you are starting a treatment or adjusting mid-journey.

Dosing Initiation & Review

Simple drawing of a smiling face with closed eyes and a curved mouth.

Semaglutide and tirzepatide dosing plans tailored to align with your organization’s treatment protocols.

Customizable GLP-1 Dosing

A stopwatch icon with a purple outline inside a circular frame.

Clear Treatment Planning

Keep patient weight loss journeys on track with detailed treatment information and predictions.

A black smartphone with a purple outline on a black background.

Shareable Patient Reports

Support and motivate patients with clear and structured treatment progress reports.

Testimonials

“Having data helps you make personalized decisions and makes you more engaged with your weight loss journey.”

Anonymous patient

“For a big enterprise with thousands of patients and many providers, I think it’s a very valuable tool.”


Dr. Odhett Cojocaru
Internist & Obesity Specialist

“It makes me feel engaged and positive, taking an active part in my health journey.”


Anonymous patient

Why WeDosify

IP Protected

Underpinned by a patent portfolio established over the last 6 years, our IP enables the creation of proprietary innovative dosage solutions that enhance clinical outcomes.

Work-flow Friendly

Fast onboarding and seamless implementation — integrates effortlessly into clinical workflows and supports shared decision-making.

Enhanced Future Value

Extensive patents covering GLP-1 & incretin drug classes, ensuring exclusivity and differentiation for any future dose personalized GLP-1 or incretin therapy.

Evidence-based Insights

Built on insights from 29 studies (including STEP 12, STEP 23, SURMOUNT 14 and SURMOUNT 25) and 15,000+ patient profiles, developed in collaboration with clinicians.

Partner Customizable

Our dose prediction model is refined and iterated to represent your patient population, with product features customizable to meet your requirements.

Intelligent Dosing

Our treatment response algorithms seamlessly refine forecasts for each patient as their data accumulates, making predictions more personalized.

Truly Personalized Care

Supports clinical decision-making tailored to the individual, driving greater patient retention and weight loss.

Easy Integration

With a fast and straightforward route to API integration and implementation, we can unlock immediate value for your organization.

Closed Loop Medicine

WeDosify is manufactured by Closed Loop Medicine (CLM). Closed Loop Medicine specializes in data-driven personalized dosing solutions, combining real-world pharmacology with data science to deliver predictive insights that help patients stay on treatment and achieve better health outcomes.

Medical device certification logo with IS0 13485 quality management standard text.
Certification badge for ISO/IEC 27001:2022, certified by Prescient

Privacy Statement

WeDosify does not collect, store or transmit any patient data. Clinicians enter anonymized inputs to generate predictions, which are processed in real-time and never saved.

The use of the tool is fully compliant with clinical privacy standards, and no identifiable patient information is required at any point. More details available in the Privacy Policy.

References

1. Gasoyan H, Pfoh ER, Schulte R, Le P, Rothberg MB. Early- and later-stage persistence with antiobesity medications: A retrospective cohort study. Obesity (Silver Spring). 2024;32(3):486-493. doi:10.1002/oby.23952 

2.Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183 

3. Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971-984. doi:10.1016/S0140-6736(21)00213-0. 

4.Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038

5. Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023;402(10402):613-626. doi:10.1016/S0140-6736(23)01200-X